Nelly ZIADE 🍀 Nellziade

6 days 13 hours ago

Many drugs in the pipeline for #Systemic_Sclerosis In particular, stay tuned for: 🔺Nerandomilast (PDE4i) in ILD 🔺CAR T cells (obviously): big RCT trials planned 🔺Bispecific T cell engagers: Teclistamab #HOT session Pr Oliver Distler #EULAR2026 @RheumNow https://t.co/I7HQtfwuW0

What Happens when CAR-T Fails Managing Disease Recurrence

6 days 14 hours ago

Day 1 + 2 Recap: EULAR 2026

1 week ago

Dr. John Cush RheumNow

1 week ago

CAR-T Cell Therapies in Refractory RMD Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare. Recent anecdotal reports suggest that CD19-directed CAR-T cell therapy may https://t.co/lXX5RjEw6a

CAR-T Reaches the Synovium: COMPARE Phase 1 in ACPA-Positive RA

Henrique Dalmolin, MD

1 week ago

Treatment-refractory RA is more common than we sometimes admit. Roughly 11% of patients fail multiple b/tsDMARD classes, and for the ACPA-positive subset, rituximab has long been the fallback. It works, but it rarely produces durable disease-free intervals. CD19 CAR T-cell therapy was always going to be the question that followed the SLE data. Until EULAR 2026, that question had no prospective answer. The plenary session changed that.

Dr. John Cush RheumNow

1 week ago

From Skepticism to Reconsideration: 4‑Year CAR‑T Outcomes in Lupus Chimeric antigen receptor (CAR) T‑cell therapy, long established in hematologic malignancies, is now emerging as a transformative approach in systemic lupus erythematosus (SLE), a disease historically managed https://t.co/Dmmw90XnuF

Janet Pope Janetbirdope

1 week ago

Sustained remission in #SLE at 5 yrs w CAR-T 8 severe SLE patients treated with autologous CD19-CAR T cells (Zorpocel; Miltenyi Biomedicine) #antiDNA and #SLEDAI #antiSm ➡️prolonged suppression Big ? - how long will it work for Impressive! @RheumNow #EULAR2026 #EULARbest #729 https://t.co/8iOSImX3w6

https://x.com/Janetbirdope/status/2062543128117059926/photo/1

Md Yuzaiful Md Yusof Yuz6Yusof

1 week ago

#EULAR2026 POS0079 Phase I study of “Off-the-Shelf” CD19 CAR-T FT819 in N=13 #SLE pts with/-out LN reported favourable efficacy and safety particularly with Bendamustine conditioning. Advantages: scalable and requires minimal or no conditioning. Will move on to Phase II @RheumNow https://t.co/2rt646Qf0T

https://x.com/Yuz6Yusof/status/2062529425246240921/photo/1

Aurelie Najm AurelieRheumo

1 week ago

COMPARE Ph I trial CD19 CAR T-cell ACPA+ refractory RA 6 pts median 6.5 b/tsDMARDs Single CAR T infusion after lymphodepletion Safety -CRS only grade 1–2 (no severe events) -No ICANS -Transient neutropenia -No unexpected toxicities Efficacy DAS28-CRP ↓ ~41% median 50% achieved https://t.co/cdEfGKcJUp

https://x.com/AurelieRheumo/status/2062491277191438681/photo/1

Md Yuzaiful Md Yusof Yuz6Yusof

1 week ago

#EULAR2026 POS0729 Longer-term data of autologous CD19 CAR-T appear favourable in #SLE. 4-year data of the initial 8 patients treated at Erlangen remained in GC- and IS-free remission. Infection profile declined over time apart from some blips during COVID pandemic @RheumNow https://t.co/QZMxA2CK33

https://x.com/Yuz6Yusof/status/2062475626238369985/photo/1

Md Yuzaiful Md Yusof Yuz6Yusof

1 week ago

#EULAR2026 OP0170 Progress of CAR-T in myositis? Phase 1 of rese-cel autologous CD19 CAR-T (advantage: humanised, 4-1BB Co-stimulatory Domain to enhance cells expansion) showed no safety signals and early efficacy in 4 IIM subtypes. Both anti-synthetase pts relapsed @RheumNow https://t.co/QisldedCti

https://x.com/Yuz6Yusof/status/2062465291452330038/photo/1

Md Yuzaiful Md Yusof Yuz6Yusof

1 week ago

#EULAR2026 OP Are we closer to controlled trials of CAR-T? Miv-cel KYV-101 autologous CD19 CAR-T reported efficacy and safety profile in 6 patients with severe refractory #RA (median prior bDMARDs: 6) in Phase I COMPARE. Will proceed to Phase II with RTX as a comparator @RheumNow https://t.co/Rb4BFgBDZE

https://x.com/Yuz6Yusof/status/2062458622936760812/photo/1

Janet Pope Janetbirdope

1 week ago

Which ‘CAR’ to drive in #SLE? Comparison of #CD19 #CAR-T #allogenic vs #Autologous ➡️ comparing #molecular #responses from 2 #lupus studies N=12 Both improved cytokine signatures For #IFN & #neutrophils Results similar not identical ?either #POS0678 #EULAR2026 @RheumNow https://t.co/Lcpv3qJ6tU

Dr. John Cush RheumNow

1 week ago

COMPARE Trial: CAR-T Cell Rx in 6 refractory active CCP+ RA pts (failed 4-7 prior b/tsDMARDs). After lymphodepletion w/ CTX + fludarabine, B cells depleted w/ neutropenia. Significant drops in CCP, RF, and DAS28, but at wk 12 only 50% ACR 20 response. Encouraging data but not https://t.co/txm32NkOKW